• 南京醫(yī)科大學第一附屬醫(yī)院肝膽胰外科（南京210029）;

目的  探討syndecan-1蛋白在肝細胞肝癌的表達及與臨床病理參數(shù)的關(guān)系
方法  采用免疫組化ABC法檢測syndecan-1在肝細胞肝癌中的表達。
結(jié)果  發(fā)現(xiàn)在47例肝癌組織中syndecan-1陰性表達28例，其分化不良的肝癌syndecan-1陰性表達率高于分化較好者（分別為78.3%，41.7%，兩者相比Ｐ＜0.05）； 直徑＞5cm的肝癌syndecan-1陰性表達率高于直徑≤5cm肝癌（分別為81.0%，42.3%，兩者相比Ｐ＜0.01）； 大體或鏡下有癌栓者syndecan-1陰性表達率高于無癌栓的肝癌（分別為84.2%，42.9%，兩者相比Ｐ＜0.01）。syndecan-1的陰性表達與患者血清甲胎蛋白水平及Child分級均無明顯的相關(guān)性（Ｐ＞0.05）。
結(jié)論  syndecan -1的低表達與肝癌增大、分化程度低、侵襲轉(zhuǎn)移發(fā)生等惡性表型相關(guān)，可能對這些表型起負調(diào)節(jié)作用，可視為抑癌基因。

引用本文： 王學浩,成峰,錢建民,張峰,李相成. syndecan-1蛋白的表達與肝細胞肝癌惡性表型的研究. 中國普外基礎(chǔ)與臨床雜志, 2001, 8(4): 239-241. doi: 復制

1. Inki P, Joensuu H, Grenman R, et al. Association between syndecan1 expression and clinical outcome in squamous cell carcinoma of the head and neck 〔Ｊ〕. Br J Cancer, 1994; 70(2)∶319.
2. Bernfield M, Kokenyesi P, Kato M, et al. Biology of the syndecans 〔Ｊ〕. Ann Rev Biochem, 1992; 8∶365.
3. Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver 〔Ｊ〕. Hepatology, 1995; 21(4)∶950.
4. Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumors 〔Ｊ〕. J Pathol, 1998; 185(3)∶290.
5. Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan1 in human hepatocellular carcinoma with high metastatic potential 〔Ｊ〕. Int J Cancer, 1997; 74(5)∶482.
6. Mali M, Andfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan1 ectodomain 〔Ｊ〕. J Biol Chem, 1994; 269(45)∶27795.
7. KumarSingh S, Jacobs W, Dhaene K, et al. Syndecan1 expression in maligant mesothlioma: correlation with differentiation, wtl expression, and clinical outcome 〔Ｊ〕. J Pathol, 1998; 186(3)∶300.
8. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection 〔Ｊ〕. Gastroenterology, 1994; 106(3)∶720.
  1. 1. Inki P, Joensuu H, Grenman R, et al. Association between syndecan1 expression and clinical outcome in squamous cell carcinoma of the head and neck 〔Ｊ〕. Br J Cancer, 1994; 70(2)∶319.
  2. 2. Bernfield M, Kokenyesi P, Kato M, et al. Biology of the syndecans 〔Ｊ〕. Ann Rev Biochem, 1992; 8∶365.
  3. 3. Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver 〔Ｊ〕. Hepatology, 1995; 21(4)∶950.
  4. 4. Roskams T, De Vos R, David G, et al. Heparan sulphate proteoglycan expression in human primary liver tumors 〔Ｊ〕. J Pathol, 1998; 185(3)∶290.
  5. 5. Matsumoto A, Ono M, Fujimoto Y, et al. Reduced expression of syndecan1 in human hepatocellular carcinoma with high metastatic potential 〔Ｊ〕. Int J Cancer, 1997; 74(5)∶482.
  6. 6. Mali M, Andfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan1 ectodomain 〔Ｊ〕. J Biol Chem, 1994; 269(45)∶27795.
  7. 7. KumarSingh S, Jacobs W, Dhaene K, et al. Syndecan1 expression in maligant mesothlioma: correlation with differentiation, wtl expression, and clinical outcome 〔Ｊ〕. J Pathol, 1998; 186(3)∶300.
  8. 8. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection 〔Ｊ〕. Gastroenterology, 1994; 106(3)∶720.